Wnt drug discovery: Weaving through the screens, patents and clinical trials

Cancers

Volumn 8, Issue 9, 2016, Pages

  Lu, Benjamin ^a   Green, Brooke A ^a   Farr, Jacqueline M ^a   Lopes, Flávia C M ^a   Van Raay, Terence J ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Cancer; Clinical trials; HEK293; Inhibitors; Patents; Screen; SUPERTOPFlash; TOPflash; Wnt; catenin

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BETA CATENIN; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; T CELL FACTOR PROTEIN; WNT PROTEIN;

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG SCREENING; DRUG TARGETING; HUMAN; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATENT; REVIEW; WNT SIGNALING PATHWAY;

EID: 84991063245     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers8090082     Document Type: Review

References (115)

1. Fuchs, E. The tortoise and the hair: Slow-cycling cells in the stem cell race. Cell 2009, 137, 811-819. [CrossRef] [PubMed]
2. Haegebarth, A.; Clevers, H. Wnt signaling, lgr5, and stem cells in the intestine and skin. Am. J. Pathol. 2009, 174, 715-721. [CrossRef] [PubMed]
3. Wodarz, A.; Nusse, R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 1998, 14, 59-88. [CrossRef] [PubMed]
4. Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 2006, 127, 469-480. [CrossRef] [PubMed]
5. Freese, J.L.; Pino, D.; Pleasure, S.J. Wnt signaling in development and disease. Neurobiol. Dis. 2010, 38, 148-153. [CrossRef] [PubMed]
6. Logan, C.Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20, 781-810. [CrossRef] [PubMed]
7. Angers, S.; Moon, R.T. Proximal events in Wnt signal transduction. Nat. Rev. Mol. Cell Biol. 2009, 10, 468-477. [CrossRef] [PubMed]
8. De Sousa, E.M.; Vermeulen, L.; Richel, D.; Medema, J.P. Targeting Wnt signaling in colon cancer stem cells. Clin. Cancer Res. 2010, 17, 647-653. [CrossRef] [PubMed]
9. Duchartre, Y.; Kim, Y.M.; Kahn, M. The Wnt signaling pathway in cancer. Crit. Rev. Oncol. Hematol. 2016, 99, 141-149. [CrossRef] [PubMed]
10. Le, P.N.; McDermott, J.D.; Jimeno, A. Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28. Pharmacol. Ther. 2015, 146, 1-11. [CrossRef] [PubMed]
11. Polakis, P. Drugging Wnt signalling in cancer. EMBO J. 2012, 31, 2737-2746. [CrossRef] [PubMed]
12. Emami, K.H.; Nguyen, C.; Ma, H.; Kim, D.H.; Jeong, K.W.; Eguchi, M.; Moon, R.T.; Teo, J.L.; Kim, H.Y.; Moon, S.H, et al. A small molecule inhibitor of β-catenin/CREB-binding protein transcription. Proc. Natl. Acad. Sci. USA 2004, 101, 12682-12687. [CrossRef] [PubMed]
13. Liu, J.; Pan, S.; Hsieh, M.H.; Ng, N.; Sun, F.; Wang, T.; Kasibhatla, S.; Schuller, A.G.; Li, A.G.; Cheng, D, et al. Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proc. Natl. Acad. Sci. USA 2013, 110, 20224-20229. [CrossRef] [PubMed]
14. Ma, H.; Nguyen, C.; Lee, K.S.; Kahn, M. Differential roles for the coactivators cbp and p300 on TCF/β-catenin-mediated survivin gene expression. Oncogene 2005, 24, 3619-3631. [CrossRef] [PubMed]
15. De Vrieze, E.; Zethof, J.; Schulte-Merker, S.; Flik, G.; Metz, J.R. Identification of novel osteogenic compounds by an ex-vivo sp7:Luciferase zebrafish scale assay. Bone 2015, 74, 106-113. [CrossRef] [PubMed]
16. Li, X.; Shan, J.; Chang, W.; Kim, I.; Bao, J.; Lee, H.J.; Zhang, X.; Samuel, V.T.; Shulman, G.I.; Liu, D, et al. Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism. Proc. Natl. Acad. Sci. USA 2012, 109, 11402-11407. [CrossRef] [PubMed]
17. Bertoldo, D.; Khan, M.M.; Dessen, P.; Held, W.; Huelsken, J.; Heinis, C. Phage selection of peptide macrocycles against β-catenin to interfere with Wnt signaling. Chem. Med. Chem. 2016, 11, 834-839. [CrossRef] [PubMed]
18. Anton, R.; Chatterjee, S.S.; Simundza, J.; Cowin, P.; Dasgupta, R. A systematic screen for micro-RNAs regulating the canonical Wnt pathway. PLoS ONE 2011, 6, e26257. [CrossRef] [PubMed]
19. Chen, Q.; Su, Y.; Wesslowski, J.; Hagemann, A.I.; Ramialison, M.; Wittbrodt, J.; Scholpp, S.; Davidson, G. Tyrosine phosphorylation of LRP6 by Src and Fer inhibits Wnt/β-catenin signalling. EMBO Rep 2014, 15, 1254-1267. [CrossRef] [PubMed]
20. Choi, H.; Gwak, J.; Cho, M.; Ryu, M.J.; Lee, J.H.; Kim, S.K.; Kim, Y.H.; Lee, G.W.; Yun, M.Y.; Cuong, N.M, et al. Murrayafoline a attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Biochem. Biophys. Res. Commun. 2010, 391, 915-920. [CrossRef] [PubMed]
21. Chuang, K.A.; Lieu, C.H.; Tsai, W.J.; Wu, M.H.; Chen, Y.C.; Liao, J.F.; Wang, C.C.; Kuo, Y.C. Evaluation of anti-Wnt/β-catenin signaling agents by PGL4-top transfected stable cells with a luciferase reporter system. Braz. J. Med. Biol. Res. 2010, 43, 931-941. [CrossRef] [PubMed]
22. Coombs, G.S.; Schmitt, A.A.; Canning, C.A.; Alok, A.; Low, I.C.; Banerjee, N.; Kaur, S.; Utomo, V.; Jones, C.M.; Pervaiz, S, et al. Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene 2012, 31, 213-225. [CrossRef] [PubMed]
23. Coombs, G.S.; Yu, J.; Canning, C.A.; Veltri, C.A.; Covey, T.M.; Cheong, J.K.; Utomo, V.; Banerjee, N.; Zhang, Z.H.; Jadulco, R.C, et al. Wls-dependent secretion of Wnt3a requires Ser209 acylation and vacuolar acidification. J. Cell Sci. 2010, 123, 3357-3367. [CrossRef] [PubMed]
24. Dale, T.; Clarke, P.A.; Esdar, C.; Waalboer, D.; Adeniji-Popoola, O.; Ortiz-Ruiz, M.J.; Mallinger, A.; Samant, R.S.; Czodrowski, P.; Musil, D, et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nat. Chem. Bio. 2015, 11, 973-980. [CrossRef] [PubMed]
25. Duraiswamy, A.J.; Lee, M.A.; Madan, B.; Ang, S.H.; Tan, E.S.; Cheong, W.W.; Ke, Z.; Pendharkar, V.; Ding, L.J.; Chew, Y.S, et al. Discovery and optimization of a porcupine inhibitor. J. Med. Chem. 2015, 58, 5889-5899. [CrossRef] [PubMed]
26. Ewan, K.; Pajak, B.; Stubbs, M.; Todd, H.; Barbeau, O.; Quevedo, C.; Botfield, H.; Young, R.; Ruddle, R.; Samuel, L, et al. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res. 2010, 70, 5963-5973. [CrossRef] [PubMed]
27. Gong, Y.; Bourhis, E.; Chiu, C.; Stawicki, S.; DeAlmeida, V.I.; Liu, B.Y.; Phamluong, K.; Cao, T.C.; Carano, R.A.; Ernst, J.A, et al. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS ONE 2010, 5, e12682. [CrossRef] [PubMed]
28. Gurney, A.; Axelrod, F.; Bond, C.J.; Cain, J.; Chartier, C.; Donigan, L.; Fischer, M.; Chaudhari, A.; Ji, M.; Kapoun, A.M, et al. Wnt pathway inhibition via the targeting of frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci. USA 2012, 109, 11717-11722. [CrossRef] [PubMed]
29. Gwak, J.; Lee, J.H.; Chung, Y.H.; Song, G.Y.; Oh, S. Small molecule-based promotion of PKCα-mediated β-catenin degradation suppresses the proliferation of CRT-positive cancer cells. PLoS ONE 2012, 7, e46697. [CrossRef] [PubMed]
30. Huang, S.M.; Mishina, Y.M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G.A.; Charlat, O.; Wiellette, E.; Zhang, Y.; Wiessner, S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461, 614-620. [CrossRef] [PubMed]
31. Lu, D.; Liu, J.X.; Endo, T.; Zhou, H.; Yao, S.; Willert, K.; Schmidt-Wolf, I.G.; Kipps, T.J.; Carson, D.A. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/β-catenin pathway. PLoS ONE 2009, 4, e8294. [CrossRef] [PubMed]
32. Madan, B.; Walker, M.P.; Young, R.; Quick, L.; Orgel, K.A.; Ryan, M.; Gupta, P.; Henrich, I.C.; Ferrer, M.; Marine, S, et al. Usp6 oncogene promotes Wnt signaling by deubiquitylating frizzleds. Proc. Natl. Acad. Sci. USA 2016, 113, E2945-E2954. [CrossRef] [PubMed]
33. Mallinger, A.; Crumpler, S.; Pichowicz, M.; Waalboer, D.; Stubbs, M.; Adeniji-Popoola, O.; Wood, B.; Smith, E.; Thai, C.; Henley, A.T, et al. Discovery of potent, orally bioavailable, small-molecule inhibitors of Wnt signaling from a cell-based pathway screen. J. Med. Chem. 2015, 58, 1717-1735. [CrossRef] [PubMed]
34. McCulloch, M.W.; Coombs, G.S.; Banerjee, N.; Bugni, T.S.; Cannon, K.M.; Harper, M.K.; Veltri, C.A.; Virshup, D.M.; Ireland, C.M. Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. Bioorg. Med. Chem. 2009, 17, 2189-2198. [CrossRef] [PubMed]
35. Mori, N.; Toume, K.; Arai, M.A.; Koyano, T.; Kowithayakorn, T.; Ishibashi, M. 2-methoxy-1,4-naphthoquinone isolated from impatiens balsamina in a screening program for activity to inhibit Wnt signaling. J. Nat. Med. 2011, 65, 234-236. [CrossRef] [PubMed]
36. Naik, S.; Dothager, R.S.; Marasa, J.; Lewis, C.L.; Piwnica-Worms, D. Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant β -catenin activation in colon cancer. Clin. Cancer Res. 2009, 15, 7529-7537. [CrossRef] [PubMed]
37. Narwal, M.; Koivunen, J.; Haikarainen, T.; Obaji, E.; Legala, O.E.; Venkannagari, H.; Joensuu, P.; Pihlajaniemi, T.; Lehtio, L. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity. J. Med. Chem. 2013, 56, 7880-7889. [CrossRef] [PubMed]
38. Ohishi, K.; Toume, K.; Arai, M.A.; Koyano, T.; Kowithayakorn, T.; Mizoguchi, T.; Itoh, M.; Ishibashi, M. 9-hydroxycanthin-6-one, a β-carboline alkaloid from eurycoma longifolia, is the first wnt signal inhibitor through activation of glycogen synthase kinase 3β without depending on casein kinase 1α. J. Nat. Prod. 2015, 78, 1139-1146. [CrossRef] [PubMed]
39. Park, H.Y.; Toume, K.; Arai, M.A.; Koyano, T.; Kowithayakorn, T.; Ishibashi, M. B-sitosterol and flavonoids isolated from bauhinia malabarica found during screening for Wnt signaling inhibitory activity. J. Nat. Med. 2014, 68, 242-245. [CrossRef] [PubMed]
40. Park, S.; Gwak, J.; Cho, M.; Song, T.; Won, J.; Kim, D.E.; Shin, J.G.; Oh, S. Hexachlorophene inhibits Wnt/β-catenin pathway by promoting siah-mediated β-catenin degradation. Mol. Pharmacol. 2006, 70, 960-966. [CrossRef] [PubMed]
41. Park, S.; Kim, J.H.; Kim, J.E.; Song, G.Y.; Zhou, W.; Goh, S.H.; Na, M.; Oh, S. Cytotoxic activity of aeroplysinin-1 against colon cancer cells by promoting β-catenin degradation. Food. Chem. Toxicol. 2016, 93, 66-72. [CrossRef] [PubMed]
42. Poulsen, A.; Ho, S.Y.; Wang, W.; Alam, J.; Jeyaraj, D.A.; Ang, S.H.; Tan, E.S.; Lin, G.R.; Cheong, V.W.; Ke, Z, et al. Pharmacophore model for wnt/porcupine inhibitors and its use in drug design. J. Chem. Inf. Model. 2015, 55, 1435-1448. [CrossRef] [PubMed]
43. Toume, K.; Kamiya, K.; Arai, M.A.; Mori, N.; Sadhu, S.K.; Ahmed, F.; Ishibashi, M. Xylogranin b: A potent Wnt signal inhibitory limonoid from xylocarpus granatum. Org. Lett. 2013, 15, 6106-6109. [CrossRef] [PubMed]
44. Zahoor, M.; Cha, P.H.; Min do, S.; Choi, K.Y. Indirubin-3′-oxime reverses bone loss in ovariectomized and hindlimb-unloaded mice via activation of the Wnt/β-catenin signaling. J. Bone Miner. Res. 2014, 29, 1196-1205. [CrossRef] [PubMed]
45. Zhang, J.; Kong, L.M.; Zhan, R.; Ye, Z.N.; Pu, J.X.; Sun, H.D.; Li, Y. Two natural ent-kauranoids as novel Wnt signaling inhibitors. Nat. Prod. Bioprospect. 2014, 4, 135-140. [CrossRef] [PubMed]
46. Zhang, Q.; Major, M.B.; Takanashi, S.; Camp, N.D.; Nishiya, N.; Peters, E.C.; Ginsberg, M.H.; Jian, X.; Randazzo, P.A.; Schultz, P.G, et al. Small-molecule synergist of the wnt/β-catenin signaling pathway. Proc. Natl. Acad. Sci. USA 2007, 104, 7444-7448. [CrossRef] [PubMed]
47. Zhang, W.; Sviripa, V.; Kril, L.M.; Chen, X.; Yu, T.; Shi, J.; Rychahou, P.; Evers, B.M.; Watt, D.S.; Liu, C. Fluorinated N,N-dialkylaminostilbenes for Wnt pathway inhibition and colon cancer repression. J. Med. Chem. 2011, 54, 1288-1297. [CrossRef] [PubMed]
48. Li, X.; Ohtsuki, T.; Koyano, T.; Kowithayakorn, T.; Ishibashi, M. New Wnt/β-catenin signaling inhibitors isolated from eleutherine palmifolia. Chem. Asian. J. 2009, 4, 540-547. [CrossRef] [PubMed]
49. Song, S.; Christova, T.; Perusini, S.; Alizadeh, S.; Bao, R.Y.; Miller, B.W.; Hurren, R.; Jitkova, Y.; Gronda, M.; Isaac, M, et al. Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res. 2011, 71, 7628-7639. [CrossRef] [PubMed]
50. Chen, J.; Wang, C.; Lan, W.; Huang, C.; Lin, M.; Wang, Z.; Liang, W.; Iwamoto, A.; Yang, X.; Liu, H. Gliotoxin inhibits proliferation and induces apoptosis in colorectal cancer cells. Mar. Drugs 2015, 13, 6259-6273. [CrossRef] [PubMed]
51. Hwang, S.Y.; Deng, X.; Byun, S.; Lee, C.; Lee, S.J.; Suh, H.; Zhang, J.; Kang, Q.; Zhang, T.; Westover, K.D, et al. Direct targeting of β-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/β-catenin signaling. Cell. Rep. 2016, 16, 28-36. [CrossRef] [PubMed]
52. Lan, L.; Appelman, C.; Smith, A.R.; Yu, J.; Larsen, S.; Marquez, R.T.; Liu, H.; Wu, X.; Gao, P.; Roy, A, et al. Natural product (−)-gossypol inhibits colon cancer cell growth by targeting rna-binding protein musashi-1. Mol. Oncol. 2015, 9, 1406-1420. [CrossRef] [PubMed]
53. Lee, S.Y.; Lim, T.G.; Chen, H.; Jung, S.K.; Lee, H.J.; Lee, M.H.; Kim, D.J.; Shin, A.; Lee, K.W.; Bode, A.M, et al. Esculetin suppresses proliferation of human colon cancer cells by directly targeting β-catenin. Cancer Prev. Res. 2013, 6, 1356-1364. [CrossRef] [PubMed]
54. Yao, H.; Ashihara, E.; Strovel, J.W.; Nakagawa, Y.; Kuroda, J.; Nagao, R.; Tanaka, R.; Yokota, A.; Takeuchi, M.; Hayashi, Y, et al. Av-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer J. 2011. [CrossRef] [PubMed]
55. Shan, B.E.; Wang, M.X.; Li, R.Q. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/β-catenin signaling pathway. Cancer Invest. 2009, 27, 604-612. [CrossRef] [PubMed]
56. Canal, F.; Anthony, E.; Lescure, A.; Del Nery, E.; Camonis, J.; Perez, F.; Ragazzon, B.; Perret, C. A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1. BMC Cancer 2015. [CrossRef] [PubMed]
57. Conrad, W.; Major, M.B.; Cleary, M.A.; Ferrer, M.; Roberts, B.; Marine, S.; Chung, N.; Arthur, W.T.; Moon, R.T.; Berndt, J.D, et al. FAM129B is a novel regulator of Wnt/β-catenin signal transduction in melanoma cells. F1000Research 2013. [CrossRef]
58. De Robertis, A.; Valensin, S.; Rossi, M.; Tunici, P.; Verani, M.; De Rosa, A.; Giordano, C.; Varrone, M.; Nencini, A.; Pratelli, C, et al. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells. Mol. Cancer Ther. 2013, 12, 1180-1189. [CrossRef] [PubMed]
59. Gonsalves, F.C.; Klein, K.; Carson, B.B.; Katz, S.; Ekas, L.A.; Evans, S.; Nagourney, R.; Cardozo, T.; Brown, A.M.; DasGupta, R. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl. Acad. Sci. USA 2011, 108, 5954-5963. [CrossRef] [PubMed]
60. Gurrola-Diaz, C.M.; Garcia-Lopez, P.M.; Gulewicz, K.; Pilarski, R.; Dihlmann, S. Inhibitory mechanisms of two Uncaria tomentosa extracts affecting the Wnt-signaling pathway. Phytomedicine 2011, 18, 683-690. [CrossRef] [PubMed]
61. Handeli, S.; Simon, J.A. A small-molecule inhibitor of TCF/β-catenin signaling down-regulates ppargamma and ppardelta activities. Mol. Cancer Ther. 2008, 7, 521-529. [CrossRef] [PubMed]
62. James, R.G.; Biechele, T.L.; Conrad, W.H.; Camp, N.D.; Fass, D.M.; Major, M.B.; Sommer, K.; Yi, X.; Roberts, B.S.; Cleary, M.A, et al. Bruton’s tyrosine kinase revealed as a negative regulator of Wnt-β-catenin signaling. Sci. Signal 2009. [CrossRef] [PubMed]
63. Lee, S.B.; Park, Y.I.; Dong, M.S.; Gong, Y.D. Identification of 2,3,6-trisubstituted quinoxaline derivatives as a Wnt2/β-catenin pathway inhibitor in non-small-cell lung cancer cell lines. Bioorg. Med. Chem. Lett. 2010, 20, 5900-5904. [CrossRef] [PubMed]
64. Mazur, M.; Bujak, A.; Matloka, M.; Janowska, S.; Gunerka, P.; Bojarski, L.; Stanczak, A.; Klejman, A.; Bednarek, A.; Lamparska-Przybysz, M, et al. Cell-based assay for low- and high-scale screening of the Wnt/β-catenin signaling modulators. Anal. Biochem. 2015, 475, 56-67. [CrossRef]
65. Okada-Iwasaki, R.; Takahashi, Y.; Watanabe, Y.; Ishida, H.; Saito, J.I.; Nakai, R.; Asai, A. The discovery and characterization of K-756, a novel Wnt/β-catenin pathway inhibitor targeting tankyrase. Mol. Cancer Ther. 2016, 15, 1525-1534. [CrossRef] [PubMed]
66. Zhao, W.N.; Cheng, C.; Theriault, K.M.; Sheridan, S.D.; Tsai, L.H.; Haggarty, S.J. A high-throughput screen for Wnt/β-catenin signaling pathway modulators in human IPSC-derived neural progenitors. J. Biomol. Screen 2012, 17, 1252-1263. [CrossRef] [PubMed]
67. James, R.G.; Davidson, K.C.; Bosch, K.A.; Biechele, T.L.; Robin, N.C.; Taylor, R.J.; Major, M.B.; Camp, N.D.; Fowler, K.; Martins, T.J, et al. WIKI4, a novel inhibitor of tankyrase and Wnt/ss-catenin signaling. PLoS ONE 2012, 7, e50457. [CrossRef] [PubMed]
68. Verkaar, F.; van der Doelen, A.A.; Smits, J.F.; Blankesteijn, W.M.; Zaman, G.J. Inhibition of Wnt/β-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Iδ/ε. Chem. Biol. 2011, 18, 485-494. [CrossRef] [PubMed]
69. Chen, M.; Wang, J.; Lu, J.; Bond, M.C.; Ren, X.R.; Lyerly, H.K.; Barak, L.S.; Chen, W. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009, 48, 10267-10274. [CrossRef] [PubMed]
70. Borchert, K.M.; Galvin, R.J.; Frolik, C.A.; Hale, L.V.; Halladay, D.L.; Gonyier, R.J.; Trask, O.J.; Nickischer, D.R.; Houck, K.A. High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells. Assay. Drug Dev. Technol. 2005, 3, 133-141. [CrossRef] [PubMed]
71. De la Roche, M.; Rutherford, T.J.; Gupta, D.; Veprintsev, D.B.; Saxty, B.; Freund, S.M.; Bienz, M. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid. Nat. Commun. 2012. [CrossRef] [PubMed]
72. Fang, L.; Zhu, Q.; Neuenschwander, M.; Specker, E.; Wulf-Goldenberg, A.; Weis, W.I.; von Kries, J.P.; Birchmeier, W. A small-molecule antagonist of the β-catenin/tcf4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis. Cancer Res. 2016, 76, 891-901. [CrossRef] [PubMed]
73. Zhang, M.; Catrow, J.L.; Ji, H. High-throughput selectivity assays for small-molecule inhibitors of β-catenin/T-cell factor protein-protein interactions. ACS Med. Chem. Lett. 2013, 4, 306-311. [CrossRef] [PubMed]
74. An, W.F.; Germain, A.R.; Bishop, J.A.; Nag, P.P.; Metkar, S.; Ketterman, J.; Walk, M.; Weiwer, M.; Liu, X.; Patnaik, D, et al. Discovery of potent and highly selective inhibitors of GSK3B. Probe Reports From the NIH Molecular Libraries Program; National Center for Biotechnology Information: Bethesda, MD, USA, 2010.
75. Trosset, J.Y.; Dalvit, C.; Knapp, S.; Fasolini, M.; Veronesi, M.; Mantegani, S.; Gianellini, L.M.; Catana, C.; Sundstrom, M.; Stouten, P.F, et al. Inhibition of protein-protein interactions: The discovery of druglike β-catenin inhibitors by combining virtual and biophysical screening. Proteins 2006, 64, 60-67. [CrossRef] [PubMed]
76. Grandy, D.; Shan, J.; Zhang, X.; Rao, S.; Akunuru, S.; Li, H.; Zhang, Y.; Alpatov, I.; Zhang, X.A.; Lang, R.A, et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. 2009, 284, 16256-16263. [CrossRef] [PubMed]
77. Shan, J.; Shi, D.L.; Wang, J.; Zheng, J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005, 44, 15495-15503. [CrossRef] [PubMed]
78. Shan, J.; Zheng, J.J. Virtual ligand screening combined with nmr to identify DVL PDZ domain inhibitors targeting the wnt signaling. Methods Mol. Biol. 2012, 928, 17-28. [PubMed]
79. Koval, A.V.; Vlasov, P.; Shichkova, P.; Khunderyakova, S.; Markov, Y.; Panchenko, J.; Volodina, A.; Kondrashov, F.A.; Katanaev, V.L. Anti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling. Biochem. Pharmacol. 2014, 87, 571-78. [CrossRef] [PubMed]
80. Lee, H.J.; Bao, J.; Miller, A.; Zhang, C.; Wu, J.; Baday, Y.C.; Guibao, C.; Li, L.; Wu, D.; Zheng, J.J. Structure-based discovery of novel small molecule Wnt signaling inhibitors by targeting the cysteine-rich domain of frizzled. J. Biol. Chem. 2015, 290, 30596-30606. [CrossRef] [PubMed]
81. Hammad, M.A.; Azam, S.S. Structural dynamics and inhibitor searching for Wnt-4 protein using comparative computational studies. Drug Des. Devel. Ther. 2015, 9, 2449-2461. [PubMed]
82. Thorne, C.A.; Hanson, A.J.; Schneider, J.; Tahinci, E.; Orton, D.; Cselenyi, C.S.; Jernigan, K.K.; Meyers, K.C.; Hang, B.I.; Waterson, A.G, et al. Small-molecule inhibition of wnt signaling through activation of casein kinase 1α. Nat. Chem. Biol. 2010, 6, 829-836. [CrossRef] [PubMed]
83. Robertson, J.K.; Danzmann, K.; Charles, S.; Blake, K.; Olivares, A.; Bamikole, S.; Olson, M.; van Raay, T.J. Targeting the Wnt pathway in zebrafish as a screening method to identify novel therapeutic compounds. Exp. Biol. Med. 2014, 239, 169-176. [CrossRef] [PubMed]
84. Zhong, H.; Lin, S. Chemical screening with zebrafish embryos. Methods Mol. Biol. 2011, 716, 193-205. [PubMed]
85. Hao, J.; Ao, A.; Zhou, L.; Murphy, C.K.; Frist, A.Y.; Keel, J.J.; Thorne, C.A.; Kim, K.; Lee, E.; Hong, C.C. Selective small molecule targeting β-catenin function discovered by in vivo chemical genetic screen. Cell Rep. 2013, 4, 898-904. [CrossRef] [PubMed]
86. Nishiya, N.; Oku, Y.; Kumagai, Y.; Sato, Y.; Yamaguchi, E.; Sasaki, A.; Shoji, M.; Ohnishi, Y.; Okamoto, H.; Uehara, Y. A zebrafish chemical suppressor screening identifies small molecule inhibitors of the Wnt/β-catenin pathway. Chem. Biol. 2014, 21, 530-540. [CrossRef] [PubMed]
87. De Groot, R.E.; Ganji, R.S.; Bernatik, O.; Lloyd-Lewis, B.; Seipel, K.; Sedova, K.; Zdrahal, Z.; Dhople, V.M.; Dale, T.C.; Korswagen, H.C, et al. Huwe1-mediated ubiquitylation of dishevelled defines a negative feedback loop in the Wnt signaling pathway. Sci. Signal 2014. [CrossRef] [PubMed]
88. Clevers, H.; Nusse, R. Wnt/β-catenin signaling and disease. Cell 2012, 149, 1192-1205. [CrossRef] [PubMed]
89. Curtin, J.C.; Lorenzi, M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2012, 1, 563-577. [CrossRef]
90. Garber, K. Drugging the Wnt pathway: Problems and progress. J. Natl. Cancer Inst. 2009, 101, 548-550. [CrossRef] [PubMed]
91. MacDonald, B.T.; Tamai, K.; He, X. Wnt/β-catenin signaling: Components, mechanisms, and diseases. Dev. Cell 2009, 17, 9-26. [CrossRef] [PubMed]
92. Pattabiraman, D.R.; Weinberg, R.A. Tackling the cancer stem cells—What challenges do they pose? Nat. Rev. Drug Discov. 2014, 13, 497-512. [CrossRef] [PubMed]
93. Rosenbluh, J.; Wang, X.; Hahn, W.C. Genomic insights into Wnt/β-catenin signaling. Trends Pharmacol. Sci. 2014, 35, 103-109. [CrossRef] [PubMed]
94. Sawyers, C. Targeted cancer therapy. Nature 2004, 432, 294-297. [CrossRef] [PubMed]
95. Zhang, X.; Hao, J. Development of anticancer agents targeting the Wnt/β-catenin signaling. Am. J. Cancer Res. 2015, 5, 2344-2360. [PubMed]
96. Zimmerman, Z.F.; Moon, R.T.; Chien, A.J. Targeting Wnt pathways in disease. Cold Spring Harb. Perspect. Biol. 2012. [CrossRef] [PubMed]
97. Network, T.C.G.A. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330-337.
98. Regad, T. Targeting RTK signaling pathways in cancer. Cancers 2015, 7, 1758-1784. [CrossRef] [PubMed]
99. Suzuki, H.; Watkins, D.N.; Jair, K.W.; Schuebel, K.E.; Markowitz, S.D.; Chen, W.D.; Pretlow, T.P.; Yang, B.; Akiyama, Y.; Van Engeland, M, et al. Epigenetic inactivation of SFRP genes allows constitutive Wnt signaling in colorectal cancer. Nat. Genet. 2004, 36, 417-422. [CrossRef] [PubMed]
100. Mazieres, J.; He, B.; You, L.; Xu, Z.; Lee, A.Y.; Mikami, I.; Reguart, N.; Rosell, R.; McCormick, F.; Jablons, D.M. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004, 64, 4717-4720. [CrossRef] [PubMed]
101. Surana, R.; Sikka, S.; Cai, W.; Shin, E.M.; Warrier, S.R.; Tan, H.J.; Arfuso, F.; Fox, S.A.; Dharmarajan, A.M.; Kumar, A.P. Secreted frizzled related proteins: Implications in cancers. Biochim. Biophys. Acta. 2014, 1845, 53-65. [CrossRef] [PubMed]
102. Wissmann, C.; Wild, P.J.; Kaiser, S.; Roepcke, S.; Stoehr, R.; Woenckhaus, M.; Kristiansen, G.; Hsieh, J.C.; Hofstaedter, F.; Hartmann, A, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J. Pathol. 2003, 201, 204-212. [CrossRef] [PubMed]
103. Korinek, V.; Barker, N.; Morin, P.J.; van Wichen, D.; de Weger, R.; Kinzler, K.W.; Vogelstein, B.; Clevers, H. Constitutive transcriptional activation by a β-catenin-TCF complex in APC−/− colon carcinoma. Science 1997, 275, 1784-1787. [CrossRef] [PubMed]
104. Veeman, M.T.; Slusarski, D.C.; Kaykas, A.; Louie, S.H.; Moon, R.T. Zebrafish prickle, a modulator of noncanonical Wnt/fz signaling, regulates gastrulation movements. Curr. Biol. 2003, 13, 680-685. [CrossRef]
105. Albuquerque, C.; Baltazar, C.; Filipe, B.; Penha, F.; Pereira, T.; Smits, R.; Cravo, M.; Lage, P.; Fidalgo, P.; Claro, I, et al. Colorectal cancers show distinct mutation spectra in members of the canonical wnt signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosomes Cancer 2010, 49, 746-759. [CrossRef] [PubMed]
106. Christie, M.; Jorissen, R.N.; Mouradov, D.; Sakthianandeswaren, A.; Li, S.; Day, F.; Tsui, C.; Lipton, L.; Desai, J.; Jones, I.T, et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct Wnt/β-catenin signalling thresholds for tumourigenesis. Oncogene 2013, 32, 4675-4682. [CrossRef] [PubMed]
107. Leedham, S.J.; Rodenas-Cuadrado, P.; Howarth, K.; Lewis, A.; Mallappa, S.; Segditsas, S.; Davis, H.; Jeffery, R.; Rodriguez-Justo, M.; Keshav, S, et al. A basal gradient of wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts. Gut 2013, 62, 83-93. [CrossRef] [PubMed]
108. Iftikhar, H.; Rashid, S. Molecular docking studies of flavonoids for their inhibition pattern against β-catenin and pharmacophore model generation from experimentally known flavonoids to fabricate more potent inhibitors for Wnt signaling pathway. Pharmacogn. Mag. 2014, 10, S264-S271. [PubMed]
109. Koval, A.; Katanaev, V.L. Platforms for high-throughput screening of Wnt/Frizzled antagonists. Drug Discov. Today 2012, 17, 1316-1322. [CrossRef] [PubMed]
110. Bol, D.; Ebner, R. Gene expression profiling in the discovery, optimization and development of novel drugs: One universal screening platform. Pharmacogenomics 2006, 7, 227-235. [CrossRef] [PubMed]
111. Attayek, P.J.; Ahmad, A.A.; Wang, Y.; Williamson, I.; Sims, C.E.; Magness, S.T.; Allbritton, N.L. In vitro polarization of colonoids to create an intestinal stem cell compartment. PLoS ONE 2016, 11, e0153795. [CrossRef] [PubMed]
112. Drost, J.; Karthaus, W.R.; Gao, D.; Driehuis, E.; Sawyers, C.L.; Chen, Y.; Clevers, H. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 2016, 11, 347-358. [CrossRef] [PubMed]
113. Wang, Y.; Ahmad, A.A.; Shah, P.K.; Sims, C.E.; Magness, S.T.; Allbritton, N.L. Capture and 3D culture of colonic crypts and colonoids in a microarray platform. Lab Chip 2013, 13, 4625-4634. [CrossRef] [PubMed]
114. Farin, H.F.; Jordens, I.; Mosa, M.H.; Basak, O.; Korving, J.; Tauriello, D.V.; de Punder, K.; Angers, S.; Peters, P.J.; Maurice, M.M, et al. Visualization of a short-range wnt gradient in the intestinal stem-cell niche. Nature 2016, 530, 340-343. [CrossRef] [PubMed]
115. Van de Wetering, M.; Francies, H.E.; Francis, J.M.; Bounova, G.; Iorio, F.; Pronk, A.; van Houdt, W.; van Gorp, J.; Taylor-Weiner, A.; Kester, L, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015, 161, 933-945. [CrossRef] [PubMed]